Most Recent
Construction PRO
A court has rejected a bid to expand a lawsuit over a Chinese investor's $27.5 million contract to purchase a building at 99 Queen Street in Melbourne to join the matriarch of the "very wealthy" family.
Construction PRO
Spanish multinational electrical giant Iberdrola has been selected to design and operate the Victoria to New South Wales Interconnector West transmission project, part of the state's pipeline of new energy infrastructure projects.
Construction PRO
A judge has tossed a developer's challenge to a NSW Heritage Council decision on a new residential development plan for the site of the former Kenmore Hospital in Goulburn, saying there was no decision to appeal.
Construction PRO
Mining giant Rio Tinto has put the development of its steel-making decarbonisation technology BioIron on ice, opting instead to invest $35 million into Calix's zero emissions steel technology demonstration plant.
ASIC on Thursday pushed for penalties totalling $85 million against Harvey Norman and Latitude Finance, after an appeals court found the retailer’s ads touting interest-free financing were misleading.
The trustee for super fund Cbus has agreed to pay a $23.5 penalty after admitting liability in the corporate regulator's case over excessive delays in processing $20 million in death and disability claims.
The owner of Sydney developer Coronation Property has sued Fairfax for defamation over a Sydney Morning Herald story that allegedly linked him to arson attacks on two childcare centres and the home of YouTuber Jordan Shanks.
A judge has approved a "modest" $8.7 million settlement in a class action against medical device maker Exactech over allegedly defective joint replacements, saying the settlement was fair and reasonable given the limited assets of the company, whose parent has filed for bankruptcy in the US.
The corporate cop has launched two new cases and sought approval to bring a third action over financial advice that led customers to sink hundreds of millions of dollars in retirement savings into the failed Shield and First Guardian investment funds.
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.